Current European Society of Cardiology guidelines recommend both ERAs and PDE-5 inhibitors as a class I-A indication for therapy in PAH patients in New York Heart Association (NYHA) functional class II or III [5]. Here, PDE5A is linked to pulmonary arterial hypertension.